Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET

Rhea-AI Summary

BioArctic (Nasdaq Stockholm: B) will publish its third quarter report for July–September 2025 on Thursday, 13 November 2025 at 08:00 CET. An English-language audiocast with teleconference will follow the report on 13 November 2025 at 09:30 CET, where CEO Gunilla Osswald and CFO Anders Martin-Löf with colleagues will present the report and hold a Q&A.

Investors, analysts and media can join via webcast (written questions) or teleconference (verbal questions) after registration. The webcast will be available on demand on BioArctic's investor website. Contact: Oskar Bosson, VP Communications and Investor Relations.

STOCKHOLM, Nov. 4, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's third quarter report for July - September 2025 on Thursday, November 13, 2025, at 08:00 a.m. CET.

In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on November 13, at 09:30 CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, with colleagues, will present and comment on the third quarter report, followed by a Q&A-session.

If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions.

Webcast: https://bioarctic.events.inderes.com/q3-report-2025/register

If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

https://events.inderes.com/bioarctic/q3-report-2025/dial-in

The webcast will also be available on demand on BioArctic's corporate website https://www.bioarctic.com/en/investors/financial-reports-and-presentations/ after the presentation.

For more information, please contact:
Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com
Tel: + 46 704 10 71 80

This information was submitted for publication at 10:00 a.m. CET on November 3, 2025.

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/invitation-to-presentation-of-bioarctic-s-third-quarter-report-for-july---september-2025-on-november,c4261286

The following files are available for download:

https://mb.cision.com/Main/9978/4261286/3761803.pdf

Invitation to presentation of BioArctic’s third quarter report for July â€" September 2025 on November 13 at 9.30 a.m. CET

View original content:https://www.prnewswire.com/news-releases/invitation-to-presentation-of-bioarctics-third-quarter-report-for-july--september-2025-on-november-13-at-9-30-am-cet-302603815.html

SOURCE BioArctic

FAQ

When will BioArctic (B) publish its Q3 2025 report?

BioArctic will publish the Q3 2025 report on 13 November 2025 at 08:00 CET.

What time is BioArctic's Q3 2025 investor audiocast and teleconference?

The audiocast and teleconference are scheduled for 13 November 2025 at 09:30 CET.

Who will present on BioArctic's Q3 2025 call for Nasdaq Stockholm:B?

Presenters will include CEO Gunilla Osswald and CFO Anders Martin-Löf, with colleagues.

How can investors ask questions during BioArctic's Q3 2025 presentation?

You can ask written questions via the webcast or ask verbally by joining the teleconference after registration.

Where can I register to attend BioArctic's Q3 2025 audiocast or teleconference?

Registration links are provided for the webcast and teleconference; registrants receive access details and conference ID.

Will BioArctic's Q3 2025 webcast be available after the presentation?

Yes. The webcast will be available on demand on BioArctic's investor website after the presentation.